Illumina, Inc.

Illumina, Inc.

Illumina, Inc.

Date Founded




Type of Company


Employees (Worldwide)



Industrial Machinery & Manufacturing
Computer Software
Medical Support Services

Company Description

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Illumina, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, President & Director

Chief Financial Officer & Senior Vice President

Senior Vice President, General Counsel & Secretary

Chief Product & Marketing Officer

Chief Technology Officer

Chief Technology Officer

Chief Commercial Officer & Senior Vice President

Vice President & Chief Accounting Officer

Senior Vice President & Chief People Officer

Senior Vice President & Chief Medical Officer

Board of Directors

Chief Executive Officer, President & Director at Illumina, Inc.

Special Partner at New Enterprise Associates

Chief Executive Officer at GE Ventures LLC

Venture Partner-Enterprise at Lightspeed Management Co. LLC

Board of Trustees, Goldman Sachs at Intellia Therapeutics, Inc.

Paths to Illumina, Inc.
Potential Connections via
Relationship Science
Illumina, Inc.
Owners & Shareholders
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm's investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford's analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Details Hidden

Edgewood Management primarily manages large-cap growth equity portfolios which pursue long-term appreciation driven by investment in a concentrated group of US growth stocks which Edgewood considers to be of a high quality. Portfolios primarily consist of the stock of approximately twenty-two (22) publicly traded companies. To the extent that Edgewood Management may invest in any foreign companies, such investments will generally be made through the purchase of sponsored American Depository Receipts (ADR). At its discretion, the firm may also invest in companies considered to be small- or medium-cap companies. Clients may impose restrictions on investing in certain securities or certain types of securities. Edgewood Management identifies investments through research-driven fundamental analysis and employs a bottom-up approach in its investment analysis. The firm's Investment Committee incorporates both qualitative and quantitative inputs with bottom-up fundamental company analysis to identify the most appropriate securities to include in an investment portfolio. They are extremely valuation sensitive and typically have a three to five year holding period.

Recent Transactions
Details Hidden

Illumina, Inc. purchases Edico Genome Corp. from Qualcomm Ventures, Dell Technologies Capital

Details Hidden

Illumina, Inc. purchases GenoLogics Life Sciences Software, Inc. from OVP Venture Partners, GrowthWorks Capital Ltd., Yaletown Venture Partners, Inc.

Details Hidden

Illumina, Inc. purchases Myraqa, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors

Advised onIllumina, Inc. issued USD Common Stock

Legal Advisor

Advised onIllumina, Inc. purchases NextBio Corp.


Advised onIllumina, Inc. issued USD Common Stock

Investment Advisor

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Investment Advisor

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Chair, Bankruptcy & Corporate Restructuring Practice

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Advisors & Consultants
Legal Advisor

Founding Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at White & Case LLP


Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

The School commits to dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning, social concern, and scholarly inquiry.

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Total Equity
Net Profit
Enterprise Value Sales
TEVNet Income
Debt TEV
Total Debt
Enterprise Value EBITDAOperating
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Non-Profit Donations & Grants
Details Hidden

Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA.

Details Hidden

GRAIL, Inc. develops technology to early detection of cancer. It engages in developing paradigm changing clinical assays for early cancer detection, based on unique biological insights from high intensity sequencing analysis of circulating cell free nucleic acids. The company was founded in 2016 and is headquartered in Menlo Park, CA.

Details Hidden

Desktop Genetics Ltd. develops software tools to enable literal desktop genetics. It offers technologies at the intersection of biotechnology, software and laboratory automation. The firm specializes in synthetic biology, genome engineering, genome editing, functional genomics, bioinformatics, and screening. The company was founded by Victor Dillard, Riley Doyle and Edward Perello in 2012 and is headquartered in London, the United Kingdom.

Details Hidden

Executive Chairman at Kaazing Corp.

Details Hidden

Founder at Pharmacopeia LLC

Details Hidden

Chief Executive Officer & Chief Scientific Officer at Prognosys Biosciences, Inc.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

AIMS APAC REIT Real Estate Investment Trusts | Singapore, Sgp

AIMS APAC REIT operates as a real estate investment trust, managed by AIMS APAC REIT Management Ltd., which invests in a diversified portfolio of income-producing and high quality industrial real estate located throughout Asia Pacific. It includes properties that support warehousing and logistics, business parks, light industries, high-tech, and manufacturing activities. The company was founded on December 5, 2006 and is headquartered in Singapore.

Sequenom Inc. Biotechnology | San Diego, CA

Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in San Diego, CA.

Awards & Honors
Rank #912
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #36
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Illumina, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Illumina, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Illumina, Inc..